natgillin/translations-raw huggingface dataset:
The pediatric ALL may be refractory to chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT) or to chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). 
CD19xCD3 konstrukt protutijela bispecifičnog jednostrukog lanca za uporabu u postupku liječenja, poboljšanja ili uklanjanja dječje akutne limfoblastične leukemije (ALL) kod pedijatrijskog ALL pacijenta, naznačen time što navedena dječja ALL je refraktorna prema kemoterapiji ili alogenoj transplantaciji hematopoetskih matičnih stanica (HSCT).
The device for producing the sodium hypochlorite or hypochlorous acid according to claim 1, wherein that the salt is not in the water to be treated. 
Postupak obrade prema patentnom zahtjevu 11, naznačen time što je kanalizacijska cijev za vodu koja se obrađuje pod tlakom tlačna cijev instalacije u bazenu.
A pharmaceutical composition comprising a compound according to any one of the preceding claims or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient, wherein the pharmaceutical composition optionally comprises a further active ingredient selected from the group consisting of a) an antagonist of integrin a5B1, b) a cytotoxic/antiproliferative agent, c) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factor, d) an inhibitor of VEGF, e) an inhibitor of Flk-1/KDR, Flt-1, Tck/Tie-2, or Tic-1, and f) an inhibitor of phosphoinositide 3-kinase, and a mixture thereof. 
Farmaceutski preparat, koji sadrži spoj prema bilo kojem od prethodnih patentnih zahtjeva ili njegovu farmaceutski prihvatljivu sol ili solvat, i farmaceutski prihvatljiv nosač ili ekscipijens, naznačen time, da farmaceutski preparat opcijski dalje sadrži aktivni sastojak odabran iz skupine koja se sastoji od a) antagonista integrina a5B1, b) citotoksičnog / antiproliferativnog agensa, c) inhibitora faktora rasta izvedenog iz epiderma, izvedenog iz fibroblasta, ili izvedenog iz trombocita, d) inhibitora VEGF, e) inhibitora Flk-1/KDR, Flt-1, Tck/Tie-2 ili Tic-1, i inhibitora fosfoinozitid 3-kinaze i njihove mješavine.
The dosage form according to the invention is in particular suitable for preventing abuse of a pharmaceutical active ingredient selected from the group consisting of opiates, opioids, tranquillisers, preferably benzodiazepines, barbiturates, stimulants and other narcotics. 
Oblik davanja prema izumu osobito je prikladan za sprečavanje zlouporabe barem jedne farmaceutske djelatne tvari, koja je izabrana iz skupine koja obuhvaća opioide, trankvilizante, prvenstveno benzodiazepine, barbiturate, stimulanse i druga opojna sredstva.
Still a further aspect of the present invention is a method for the treatment of a patient suffering from morning stiffness and pain due to an underlying rheumatic disease and/or osteoarthritis, which comprises administering to said patient an effective amount of a glucocorticoid contained in a delayed-release dosage form, wherein said treatment is administered once daily for at lest about two weeks. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu u liječenju bolesnika koji pate od jutarnje ukočenosti i boli zbog reumatske podloge bolesti i/ili osteoartritisa, pri čemu se navedeno liječenje provodi davanjem lijeka jednom dnevno kroz najmanje dva tjedna.
The compound according to claim 36, or a pharmaceutically acceptable salt thereof, which is selected from: 5-Fluoro-2′-deoxyuridine-5′-O-[phenyl(benzoxy- L -alaninyl)]phosphate (CPF381); 
Spoj prema patentnom zahtjevu 1, izabran iz grupe koja sadrži: 5-fluoro-2'-dezoksiuridin-5'-O-[fenil(benzoksi-L-alaninil)] fosfat (CPF 381)
A compound according to any one of claims 1 to 19 for use in treating schizophrenia, schizophreniform disorder, schizoaffective disorder, cognitive disorders or pain. 
Spoj prema bilo kojem od zahtjeva 1 do 19 naznačen time da je za uporabu za liječenje shizofrenije, shizofreniformnog poremećaja, shizoafektivnog poremećaja, kognitivnih poremećaja ili boli.
Typical papers have a thickness of the order of 100 micrometers. 
Uobičajena je debljina papira reda veličina 100 mikrometara.
The anti-CTLA-4 antibody and 2'-deoxy-2',2'-difluorocytidine monohydrochloride (B-isomer), or pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to Claim 1, wherein the anti-CTLA-4 antibody is selected from the group consisting of: ipilimumab and tremelimumab. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 1, gdje je anti-CTLA-4 antitijelo odabrano iz grupe koja se sastoji od ipilimumaba i tremelimumaba.
the non-functional integrase comprises a mutation selected from the group consisting of D64E, D64V, D116N, N120K, Q148A, W235E, K264R, K266R, K273R, and combinations thereof, and 
(a) ne-funkcionalna integraza sadrži mutaciju odabranu iz skupine koja se sastoji od D64E, D64V, D116N, N120K, Q148A, W235E, K264R, K266R, K273R, i njihovih kombinacija, i
The compounds of the first aspect of this invention are compounds of the formula where: 
Spojevi iz prvog aspekta izuma su spojevi formule gdje.
The method of claim 4, wherein the Cas9 protein is transcribed and translated from a vector comprising a nucleotide sequence encoding the Cas9 protein. 
gdje je prvi nukleotidni slijed, koji kodira navedena RNA koja cilja na DNA, operabilno spregnut s promotorom; i, izborno,
Tramadol hydrochloride was used, despite tramadol not being an active ingredient which conventionally has abuse potential, because it is not governed by German narcotics legislation, so simplifying the experimental work. 
Tramadolhidroklorid je upotrebljen, iako tramadol nije djelatna tvar s uobičajenim potencijalom zlouporabe, a budući da on ne potpada pod zakon o opojnim sredstvima, time je olakšan eksperimentalni rad.
The retractable rolling shutter assembly of claim, 1 wherein each of said slats has a body portion, a top edge extending along a top portion of said body portion, a bottom edge extending along a bottom portion of said body portion; 
Sklop roletne koja se namatanjem uvlači sukladno patentnom zahtjevu 1, naznačen time što svaka od navedenih letvica ima tijelo kućišta, gornji rub koji se proteže uzduž gornjeg dijela navedenog dijela kućišta, donji rub koji se proteže uzduž donjeg dijela navedenog dijela kućišta;
A glucocorticoid contained in a delayed-release dosage form for use according to any one of the previous claims, wherein the glucocorticoid dose is exceeding 10 mg/day of prednisone or an equivalent amount of another glucocorticoid at the initiation of the therapy, and/or wherein the glucocorticoid dose is equal or less than 10 mg/day of prednisone or an equivalent amount of another glucocorticoid for maintenance therapy. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu doza glukokortikoida na početku liječenja prelazi 10 mg/dan prednizona ili odgovarajuće količine drugog glikokortikoida, i/ili pri čemu je doza glukokortikoida održavanja liječenja jednaka ili manja od 10 mg/dan prednizona ili odgovarajuće količine drugog glukokortikoida.
After recovery of anaesthesia, within 24 hours, rats were treated once daily for 6 weeks p.o. 
Nakon oporavka od anestezije unutar 24 sata, štakorima su jednom dnevno 6 tjedna p.o.
In an embodiment, the present invention provides a method of measuring quality of packetized audio and video transmission over a transmission chain. The method includes: a) providing one or more measurement detectors along the transmission chain; b) detecting, by the one or more measurement detectors, loss of bit stream packets at one or more measurement points; c) determining a unique identifier for each detected lost packet; d) sending, by the one or more measurement detectors, a list of lost packet identifiers to a central monitoring system; e) constructing, by the central monitoring system, a simulated stream for each measurement point based on a stored error-free stream and the received lost packet identifiers; and f) evaluating the simulated stream for deriving a quality score for each measurement point. 
Postupak mjerenja kvalitete audio i video prijenosa u paketima preko lanca prijenosa, naznačen time što se postupak sastoji u: a) postavljanju jednog ili više mjernih detektora duž lanca prijenosa; b) detektiranju jednim ili više mjernih detektora gubitka paketa struje bitova na jednoj ili više mjernih točaka; c) određivanju jedinstvenog identifikatora za svaki detektirani izgubljeni paket; d) slanju spiska identifikatora izgubljenih paketa iz svakog od mjernih detektora u središnji sustav za praćenje; e) konstruiranju, u središnjem sustavu za praćenje, iz uskladištene struja bez grešaka i na osnovi primljenih identifikatora izgubljenih paketa, simulirane struje za svaku od mjernih točaka; i f) procjenjivanju simuliranih struja radi dobivanje razine kvalitete za svaku od mjernih točaka duž lanca prijenosa.
lyophilizing the mature type I elastase, thereby isolating a lyophilized mature human type I elastase. 
(b) zreli tip I elastaze je zreli humani tip I elastaze, koji opcionalno sadrži sekvencu aminokiseline koja ima:
up to 0.5%), in particular composite materials in the form of dental filling materials. 
do 0.5%), a posebice na kompozitne materijale u obliku dentalnih punila.
The nano-fibrillar cellulose gel according to claim 15, characterized in that the efficiency of the nano-fibrillar cellulose gel with respect to the total energy consumption in order to achieve a certain Brookfield viscosity is higher than the efficiency of a corresponding nano-fibrillar cellulose gel having been fibrillated in the absence of fillers and/or pigments or a corresponding gel not containing filler and/or pigment. 
Gel od nanofibrilarne celuloze u skladu s patentnim zahtjevom 15, naznačen time što viskoznost gela od nanofibrilarne celuloze prema Brookfieldu je manja od viskoznosti odgovarajuće suspenzije nanofibrilarne celuloze prema Brookfieldu jer je fibrilirana u odsutnosti punila i/ili pigmenata.
A process according to any one of claims 1 to 3, characterised in that a filling medium is used which is present in a solid state of aggregation during mechanical machining, particularly at the normal temperature which prevails during mechanical machining. 
4. Postupak prema bilo kojem zahtjevu 1 do 3, naznačen time, da se upotrebljava punilo koje je tijekom mehaničke strojne obrade prisutno u krutom stanju nakupina, posebno pri normalnoj temperaturi koja prevladava tijekom mehaničke strojne obrade.
The antibody of claim 18, further comprising a VL sequence of SEQ ID NO: 6. 
SEKVENCE: 2, 3 i 4; te sekvencu varijabilne domene slabog lanca (VL) ID BR. SEKVENCE: 6.
a nucleic acid which comprises the nucleic acid sequence of SEQ ID NO: 1 a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions, 
(a) nukleinska kiselina koja sadrži nukleinsko kiselinsku sekvencu SEQ ID NO: 1, (b) nukleinska kiselina koja hibridizira sa nukleinskom kiselinom 1z (a) pod vrlo specifičnim uvjetima,
and R2 are different or the same and are independently selected from the group consisting of H; 
Z jest odabran iz skupine koju čine (CH2)m gdje m = 0, 1 ili 2, i CR4R5 gdje
Glatiramer acetate for use of claim 9, wherein the immediate post injection reaction comprises palpitations, feeling hot, flushing, hot flushes, tachycardia, dyspnoea, chest discomfort, chest pain, non-cardiac chest, asthenia, back pain, bacterial infection, chills, cyst, face edema, fever, flu syndrome, infection, neck pain, pain, migrane, syncope, tachycardia, vasodilatation, anorexia, diarrhea, gastroenteritis, gastrointestinal disorder, nausea, vomiting, ecchymosis, peripheral edema, arthralgia, agitation, anxiety, confusion, foot drop, hypertonia, nervousness, nystagmus, speech disorder, tremor, vertigo, bronchitis, dyspnea, laryngismus, rhinitis, erythema, herpes simplex, pruritus, rash, sweating, urticaria, ear pain, eye disorder, dysmenorrheal, urinary urgency, or vaginal moniliasis. 
Glatiramer acetat za uporabu prema patentnom zahtjevu 9, naznačen time, da trenutna reakcija nakon injekcije obuhvaća lupanje srca, osjećaj vrućine, crvenilo kože, napade vrućine, tahikardiju, dispneju, nelagodu u prsima, bol u prsima, nekardijalnu prsnu asteniju, bol u leđima, bakterijsku infekciju, zimicu, cistu, edem lica, groznicu, sindrom gripe, infekciju, bol u vratu, bol, migrenu, sinkopu, tahikardiju, vazodilataciju, anoreksiju, dijareju, gastroenteritis, gastrointestinalni poremećaj, mučninu, povraćanje, ekhimozu, periferni edem, bol u zglobovima, uznemirenost, tjeskobu, zbunjenost, slabost stopala, hipertoniju, nervozu, nistagmus, poremećaj govora, tremor, vrtoglavicu, bronhitis, dispneju, laringitis, rinitis, eritem, herpes simpleks, svrbež, osip, znojenje, urtikariju, bol u uhu, poremećaj u oku, dismenoreju, nagli nagon za uriniranjem ili vaginalnu kandidijazu.
dissolving or dispersing the remaining proportion of the total amount of the binder in a suitable granulation liquid; 
otapanje i raspršivanje preostalog udjela ukupne količine vezivnog sredstva u granulacijskoj tekućini;
Once the desired length has been obtained, it is possible to block the mutual sliding of the shell 3 and buttress element 5 by rotating the lever 30 towards the lateral surface of the sole 2 and fixing it thereto by means of the introduction of one of the small pins 31 in the fifth hole 32 provided in the lever 30 itself. 
Kada se treba dobiti željena duljina, moguće je blokirati uzajamno klizanje plašta 3 i potpornog elementa 5 okretanjem poluge 30 prema obodnoj površini potplata 2 i učvršćenjem poluge na nju uvođenjem jednog od malih klinova 31 u pete rupice 32 načinjene u samoj poluzi 30.
The force of gravity will aid in the emptying the container 2, and the dispensing assembly 1 thus requires less pressure for completely emptying of the container 2 than other dispensing assemblies known in the art. 
Sila gravitacije će pomoći kod pražnjenja spremnika 2, i sklop za točenje 1 stoga zahtjeva manji pritisak za potpuno pražnjenje spremnika 2 nego drugi sklopovi za točenje poznati u stanju tehnike.
mixing the oil phase provided in step (i) with the suspension provided in step (ii) to obtain a mixture, 
(iii) miješanja uljne faze dodane u koraku (i) sa suspenzijom dodanom u koraku (ii) kako bi se dobilo smjesu,
from 100 mg to 750 mg of said quinolone carboxylic acid derivative, on an acid active basis, wherein said quinolone carboxylic acid derivative is delafloxacin or a pharmaceutically acceptable salt thereof; and 
(a) od 100 mg do 750 mg navedenog derivata kinolon karboksilne kiseline, na bazi kisele aktivne supstance, gdje je derivat kinolon karboksilne kiseline delafloksacin ili njegova farmaceutski prihvatljiva sol; 1
The pharmaceutical composition for use of claim 7, wherein the metabolic disorder is overweight, obesity, insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins, or osteoarthritis. 
Spoj za uporabu prema zahtjevu 27, naznačen time da je metabolički poremećaj prekomjerna težina, gojaznost, otpornost na inzulin, dijabetes tipa Il, hiperlipidemija, žučni kamenac, angina, hipertenzija, kratak dah, tahikardija, neplodnost, apneja u snu, bol u leđima 1 zglobovima, proširene vene, ili osteoartritis.
A pharmaceutical composition comprising: (1) a compound of the formula: or a pharmaceutically acceptable salt thereof; a NS5B polymerase inhibitor; and (3) a NS3 protease inhibitor. 
Spoj ili farmaceutski prihvatljiva sol, kako je opisano u patentnom zahtjevu 1, za upotrebu pri medicinskoj terapiji. Farmaceutski sastav koji se sastoji iz spoja iz patentnog zahtjeva 2 i inhibitora NS5B polimeraze.
is imidazolyl, triazolyl, thiazolyl, pyridyl, piperidinyl, phenyl, or oxazolyl; wherein said piperidinyl, pyridyl, imidazolyl, and phenyl are optionally substituted with C(O)CH3, CH3, CF3, Cl, F, —CN, OCH3, or N(CH3)2; and optionally substituted with up to one additional group independently selected from Cl, OCH3, and CH3; and wherein said triazolyl, oxazolyl, and thiazolyl are optionally substituted with one or two CH3 groups; 
R' je imidazolil, triazolil, tiazolil, piridil, piperidinil, fenil, ili oksazolil; pri čemu su navedeni piperidinil, piridil, imidazolil, i fenil proizvoljno supstituirani s C(O)CH3, CH3, CF3, CI, F, -CN, OCMu, ili N(CH3); i proizvoljno supstituirani s do jednom dodatnom skupinom koja je neovisno odabrana od Cl, OCH., i CHs; 1 pri čemu su navedeni triazolil, oksazolil, i tiazolil proizvoljno supstituirani s jednom ili dvije skupine CH;;
The gas diffusion electrode according to claim 8, wherein said biological fuel cell is a microbial or enzymatic fuel cell. 
Primjena plinske difuzijske elektrode u skladu s zahtjevom 8, naznačena time da je navedena goriva ćelija mikrobna ili enzimska goriva ćelija.
In a preferred embodiment, the conjugated nucleic acid molecule has one of the following formulae: 
2. < Konjugirana molekula nukleinske kiseline, naznačena time što ima jednu od sljedećih formula:
The process according to any one of aspects 1 to 10, step (III) comprising placing the pressed and heated product in a holder, and (IV) causing a reagent to flow through the holder so that the reagent flows in contact with the pressed and heated product which functionalises the product of step (II) as a chromatography medium. 
Postupak prema bilo kojem zahtjevu od 1 do 8, pri čemu se korak (III) sastoji od postavljanja prešanog i zagrijanog proizvoda u držač 1 (IV) uzrokovanja protoka reagensa kroz držač tako da reagens protječe uz kontakt s prešanim 1 zagrijanim proizvodom što funkcionalizira proizvod iz koraka (II) u sredstvo za kromatografiju.
A maleic acid salt of a compound according to Formula I: 
PATENTNI ZAHTJEVI mija s» Spoj prema Formuli I:
Figure 3 shows the structure of fast cut-off circuit 4 interposed between the output of microprocessor 6a and demultiplexer circuit 12a of first circuit section 1a. 
Slika 3 prikazuje strukturu komunikacijskog kruga brzog prekidanja 4, umetnutog između izlaza mikroprocesora 6a i demultipleksnog komunikacijskog kruga 12a prve sekcije komunikacijskih krugova la.
The dosage form of claim 1, wherein the pharmaceutically acceptable solubilizer comprises alpha tocopheryl polyethylene glycol succinate. 
Oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time, da farmaceutski prihvatljiv solubilizator sadržava barem jedno od sljedećeg: alfa tokoferil polietilen glikol sukcinat, sorbitan monolaurat i polioksietilen sorbitan monolaurat.
The variant of claim 15, comprising at least one substitution selected from the group consisting of T106N, I205T and V253N. 
Varijanta iz zahtjeva 15, naznačena time, da sadrži najmanje jednu supstituciju izabranu iz skupine koju čine T106N, 1205T i V253N.
An anti-HERV-W Env antibody for use for the treatment of progressive Multiple Sclerosis, wherein said anti-HERV-W Env antibody comprises each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 
navedeni anti-HERV-W Env ligand je antitijelo, točnije kimerno, projektirano ili humanizirano antitijelo, i još točnije IgG, poput IgG1 ili IgG4, pri čemu navedeno antitijelo sadrži svaku od regija koje određuju komplementarnost (CDR) navedenih u SEQ ID No.
The process according to claim 34, wherein said step of continuously feeding CO2, said step of extracting, and said step of feeding said fiberglass-reinforced plastic waste are carried out in such a way that a countercurrent flow is maintained within said pyrolysis chamber of: 
Postupak sukladno zahtjevima 12 i 13, pri čemu se navedeni korak stalnog dovoda CO2, navedeni korak esktrahiranja (150) i navedeni korak dovoda (110) otpada od staklenom vunom ojačane plastike (21) provode na način da se unutar komore za pirolizu (52) održava protustruja
initiate one or more features of the plurality of features in response to the DMR terminals operating under the DMR gateway and make requests for the plurality of features toward destinations belonging to another network; and transcode an over-the-air, manufacturer-specific DMR terminal registration into a SIP register message to result in the SIP proxy server perceiving and managing the DMR terminal as a SIP user agent. 
koji pod njim djeluju i zahtjevi za DMR signalizacijske/podatkovne/glasovne karakteristike prema destinacijama koje pripadaju drugoj mreži; - transkodiranje zračne, u odnosu na specifičnog proizvođača registracije DMR terminala u = SIP REGISTER/REGISTRIRAJ poruku kako bi rezultirala _SIP proksi serverom koji prima i void _ DMR terminal kao SIP korisnički agent.
ring B is 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N and NR3c; 
prsten B je 5- do 6-očlani heteroaril koji sadrži atome ugljika i 1-4 heteroatoma odabrana od N i NR3c;
This could further reduce cost of the system. Electrical Circuit 
To može dalje smanjiti cijenu sustava, 10.
The solid form of any one of items 2-8, having a thermal gravimetric analysis plot comprising a mass loss of less than about 0.5% when heated from about 25 °C to about 150 °C. 
Čvrsti oblik u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što ima grafički prikaz toplinske gravimetrijske analize koji sadrži gubitak mase manji od otprilike 0,5% prilikom grijanja od otprilike 25%C€ do otprilike 150*C.
A compound according to claim 3 or 4, wherein each of R1 and R'1, or said fused ring structure formed thereby, is optionally substituted by at least one substituent selected from the group c': fluorine and chlorine atoms, hydroxyl, linear and branched alkyl, alkylthio, hydroxyalkyl, and fluoroalkyl groups; linear and branched alkoxyl groups; trifluoromethyl; trifluoromethoxyl; -CN; alkylcarbonyl groups; alkylsulphonyl groups, and any alkyl component has from 1 to 4 carbon atoms, and wherein, when there is more than one substituent, then each said substituent is the same or different. 
Spoj prema zahtjevu 3 ili 4, naznačen time da svaki R, 1 R',, ili navedena kondenzirana prstenasta struktura koja je tako formirana, proizvoljno je supstituirana sa barem jednim supstituentom odabranim iz skupine c': atomima fluora ili klora, hidroksilom, ravnim i razgranatim alkilom, alkiltio, hidroksialkilom, te fluoroalkilnim skupinama; ravnim i razgranatim alkoksil skupinama; trifluorometilom; trifluorometoksilom; -CN; alkilkarbonilnim skupinama; alkilsulfonilnim skupinama, te bilo koja alkilna komponenta ima od 1 do 4 atoma ugljika, te pri čemu, kada postoji više od jednog supstituenta, tada je svaki navedeni supstituent isti ili različit.
The compound of claim 11 having an X-ray diffraction pattern, expressed in terms of 2 θ angles, that shows peaks at 6.0, 7.5, 8.5, 12.3, 16.0, 17.0, 18.0, 18.2, 18.7, 23.2 and 25.2 ± 0.2 degrees. 
Spoj u skladu s patentnim zahtjevom 11, naznačen time što ima uzorak difrakcije rendgenskih zraka, dan u terminima kutova 2θ, sa signalima na 6,0, 7,5, 8,5, 12,3, 16,0, 17,0, 18,0, 18,2, 18,7, 23,2 i 25,2 ± 0,2 stupnja.
According to still another embodiment the remineralized water has a Membrane Fouling Index MFI0.45 below 4, preferably below 2.5, most preferred below 2. 
SDL;s ispod 5, poželjno ispod 4, te najpoželjnije ispod 3. membrane MFI14,45 ispod 4, poželjno ispod 2.5, najpoželjnije ispod 2.
The composition for use of claim 2, wherein the ophthalmic condition is elevated intraocular pressure and the therapeutic agent is latanoprost or brimonidine. 
Pripravak za uporabu u skladu s patentnim zahtjevom 2, naznačen time, da je oftalmičko stanje povišeni intraokularni tlak, a terapijsko sredstvo je latanoprost ili brimonidin.